Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Effects of antidiabetic drugs on left ventricular function/dysfunction: a systematic review and network meta-analysis
Dapeng Zhang, Li Xu, Lefeng Wang, et al.
Cardiovascular Diabetology (2020) Vol. 19, Iss. 1
Open Access | Times Cited: 45

Showing 1-25 of 45 citing articles:

Effect of liraglutide on cardiac function in patients with type 2 diabetes mellitus: randomized placebo-controlled trial
Maurice B. Bizino, Ingrid M. Jazet, Jos J.M. Westenberg, et al.
Cardiovascular Diabetology (2019) Vol. 18, Iss. 1
Open Access | Times Cited: 121
Association between sodium–glucose cotransporter-2 inhibitors and risk of sudden cardiac death or ventricular arrhythmias: a meta-analysis of randomized controlled trials
Dimitrios Sfairopoulos, Nan Zhang, Yueying Wang, et al.
EP Europace (2021) Vol. 24, Iss. 1, pp. 20-30
Open Access | Times Cited: 60
The Cardioprotective Effects of Semaglutide Exceed Those of Dietary Weight Loss in Mice With HFpEF
Coenraad Withaar, Laura M G Meems, Edgar E. Nollet, et al.
JACC Basic to Translational Science (2023) Vol. 8, Iss. 10, pp. 1298-1314
Open Access | Times Cited: 37
Combination pharmacotherapies for cardiac reverse remodeling in heart failure patients with reduced ejection fraction: A systematic review and network meta-analysis of randomized clinical trials
Jieli Bao, Rongsheng Kan, Junhong Chen, et al.
Pharmacological Research (2021) Vol. 169, pp. 105573-105573
Closed Access | Times Cited: 41
Mechanisms Underlying Antiarrhythmic Properties of Cardioprotective Agents Impacting Inflammation and Oxidative Stress
Katarína Andelová, Barbara Szeiffová Bačová, Matúš Sýkora, et al.
International Journal of Molecular Sciences (2022) Vol. 23, Iss. 3, pp. 1416-1416
Open Access | Times Cited: 33
Effect of Glucagon-like Peptide-1 Receptor Agonists on Prognosis of Heart Failure and Cardiac Function: A Systematic Review and Meta-analysis of Randomized Controlled Trials
Huixing Liu, Di Fu, Daoquan Peng
Clinical Therapeutics (2023) Vol. 45, Iss. 1, pp. 17-30
Open Access | Times Cited: 19
Cardiorenal and other diabetes related outcomes with SGLT-2 inhibitors compared to GLP-1 receptor agonists in type 2 diabetes: nationwide observational study
Moa Lugner, Naveed Sattar, Mervete Miftaraj, et al.
Cardiovascular Diabetology (2021) Vol. 20, Iss. 1
Open Access | Times Cited: 39
Protective effects of SGLT-2 inhibitors across the cardiorenal continuum: two faces of the same coin
Ricardo Fontes‐Carvalho, Diogo Santos‐Ferreira, Itamar Raz, et al.
European Journal of Preventive Cardiology (2021) Vol. 29, Iss. 9, pp. 1352-1360
Open Access | Times Cited: 33
Improvement of Left Ventricular Global Longitudinal Strain after 6-Month Therapy with GLP-1RAs Semaglutide and Dulaglutide in Type 2 Diabetes Mellitus: A Pilot Study
Paolo Basile, Andrea Igoren Guaricci, Giuseppina Piazzolla, et al.
Journal of Clinical Medicine (2023) Vol. 12, Iss. 4, pp. 1586-1586
Open Access | Times Cited: 12
Endothelial Dysfunction: A Contributor to Adverse Cardiovascular Remodeling and Heart Failure Development in Type 2 Diabetes beyond Accelerated Atherogenesis
Aleksandra Gamrat, Michał A. Surdacki, Bernadeta Chyrchel, et al.
Journal of Clinical Medicine (2020) Vol. 9, Iss. 7, pp. 2090-2090
Open Access | Times Cited: 28
Vascular and metabolic effects of SGLT2i and GLP-1 in heart failure patients
Michele Correale, Olga Lamacchia, Michele Ciccarelli, et al.
Heart Failure Reviews (2021) Vol. 28, Iss. 3, pp. 733-744
Closed Access | Times Cited: 25
Can glucose‐lowering medications improve outcomes in non‐diabetic heart failure patients? A Bayesian network meta‐analysis
Trevor James Jun‐Ming Yeong, Aaron Shengting, Oliver Lim, et al.
ESC Heart Failure (2022) Vol. 9, Iss. 2, pp. 1338-1350
Open Access | Times Cited: 17
Lobeglitazone, a novel thiazolidinedione, for secondary prevention in patients with ischemic stroke: a nationwide nested case-control study
Joonsang Yoo, Jimin Jeon, Minyoul Baik, et al.
Cardiovascular Diabetology (2023) Vol. 22, Iss. 1
Open Access | Times Cited: 10
Effects of liraglutide on diastolic function parameters in patients with type 2 diabetes and coronary artery disease: a randomized crossover study
Preman Kumarathurai, Ahmad Sajadieh, Christian Anholm, et al.
Cardiovascular Diabetology (2021) Vol. 20, Iss. 1
Open Access | Times Cited: 21
The Therapeutic Role of SGLT-2 Inhibitors in Acute Heart Failure: From Pathophysiologic Mechanisms to Clinical Evidence with Pooled Analysis of Relevant Studies across Safety and Efficacy Endpoints of Interest
Dimitrios Patoulias, Nikolaos Fragakis, Manfredi Rizzo
Life (2022) Vol. 12, Iss. 12, pp. 2062-2062
Open Access | Times Cited: 15
New antidiabetic therapy and HFpEF: light at the end of tunnel?
Marijana Tadić, Carla Sala, Sahrai Saeed, et al.
Heart Failure Reviews (2021) Vol. 27, Iss. 4, pp. 1137-1146
Open Access | Times Cited: 20
Effect of SGLT-2 inhibitor, dapagliflozin, on left ventricular remodeling in patients with type 2 diabetes and HFrEF
Qianyu Fu, Longhua Zhou, Yuqin Fan, et al.
BMC Cardiovascular Disorders (2023) Vol. 23, Iss. 1
Open Access | Times Cited: 7
Comparative outcomes of heart failure among existent classes of anti-diabetic agents: a network meta-analysis of 171,253 participants from 91 randomized controlled trials
Daya Yang, Xin He, Huiwei Liang, et al.
Cardiovascular Diabetology (2019) Vol. 18, Iss. 1
Open Access | Times Cited: 22
The effect of glucagon‐like peptide‐1 receptor agonists on cardiac function and structure in patients with or without type 2 diabetes mellitus: An updated systematic review and meta‐analysis
Yu Zhang, Danning Yang, Qiufeng Jia, et al.
Diabetes Obesity and Metabolism (2024) Vol. 26, Iss. 6, pp. 2401-2411
Closed Access | Times Cited: 2
The Association of Echocardiographically Measured Donor Left Ventricular Mass and 1-Year Outcomes After Heart Transplantation
Christian T. O’Donnell, Natalie Tapaskar, Pablo Sanchez, et al.
JACC Heart Failure (2024) Vol. 13, Iss. 1, pp. 118-130
Closed Access | Times Cited: 2
Cardiometabolic-based chronic disease: adiposity and dysglycemia drivers of heart failure
Eduardo Thadeu de Oliveira Correia, Jeffrey I. Mechanick, Letícia Mara dos Santos Barbetta, et al.
Heart Failure Reviews (2022) Vol. 28, Iss. 1, pp. 47-61
Closed Access | Times Cited: 11
SGLT2 Inhibitor: an Emerging Pillar in Heart Failure Therapeutics?
B. Geavlete, Răzvan-Ionuț Popescu, V. Iordache, et al.
MAEDICA – a Journal of Clinical Medicine (2023) Vol. 18, Iss. 1
Open Access | Times Cited: 4
Liraglutide in the treatment of heart failure: insight from FIGHT and LIVE
Bo Liang, Ning Gu
Cardiovascular Diabetology (2020) Vol. 19, Iss. 1
Open Access | Times Cited: 11
Cardiac fibrosis: emerging agents in preclinical and clinical development
Roberto Spoladore, Giulio Falasconi, Giorgio Fiore, et al.
Expert Opinion on Investigational Drugs (2020) Vol. 30, Iss. 2, pp. 153-166
Closed Access | Times Cited: 11
Comparison of clinical outcomes and left ventricular remodeling after ST-elevation myocardial infarction between patients with and without diabetes mellitus
Naoyuki Akashi, Takunori Tsukui, Kei Yamamoto, et al.
Heart and Vessels (2021) Vol. 36, Iss. 10, pp. 1445-1456
Open Access | Times Cited: 9
Page 1 - Next Page

Scroll to top